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Chylomicron metabolism is abnormal in diabetes and the chy-
lomicron particle may play a very important role in atheroscle-
rosis. The aim of this study was to examine the effect of diabetes
on the metabolism of chylomicrons in cholesterol-fed alloxan di-
abetic and nondiabetic rabbits. Five diabetic rabbits and 5 con-
trol rabbits were given [14C]linoleic acid and [3H]cholesterol by
gavage. Lymph was collected following cannulation of the lymph
duct and radiolabelled chylomicrons were isolated by ultracen-
trifugation. The chylomicrons from each animal were injected into
pairedcontrolanddiabeticrecipients.Lymphapolipoprotein(apo)
B48, apo B100, and apo E were measured using sodium dodecyl
sulfate–polyacrylamide gradient gel electrophoresis. Mean blood
sugarofthediabeticdonorsanddiabeticrecipientswere19.7§2.3
and 17.2§3.2 mmol/L. Diabetic rabbits had signiﬁcantly
raised plasma triglyceride (10.8§13.9 versus 0.8§0.5 mmol/L,
P<0.02). There was a large increase in apo B48 in lymph chylomi-
crons in the diabetic donor animals (0.19§0.10 versus 0.04§0.02
mg/h,P<0.01)andapoB100(0.22§0.15versus0.07§0.07mg/h,
P<0.05) and a reduction in apo E on the lymph chylomicron
particle (0.27§0.01 versus 0.62§0.07 mg/mg apo B, P<0.001).
Diabetic recipients cleared both control and diabetic chylomi-
cron triglyceride signiﬁcantly more slowly than control recipients
(P<0.05). Clearance of control chylomicron cholesterol was de-
layedwheninjectedintodiabeticrecipientscomparedtowhenthese
chylomicrons were injected into control recipients (P<0.005).
Clearance of diabetic chylomicron cholesterol was signiﬁcantly
slower when injected into control animals compared to control
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chylomicron injected into control animals (P<0.02). In this an-
imal model of atherosclerosis, we have demonstrated that diabetes
leads to the production of an increased number of lipid and apo
E–deﬁcient chylomicron particles. Chylomicron particles from the
control animals were cleared more slowly by the diabetic recipi-
ent (both triglyceride and cholesterol). The chylomicron particles
obtained from the diabetic animals were cleared even more slowly
wheninjectedintothediabeticrecipient.Althoughtherewasanini-
tialdelayinclearanceofchylomicrontriglyceridefromthediabetic
particle when injected into the control animals, the clearance over
the ﬁrst 15 minutes was not signiﬁcantly different when compared
to the control chylomicron injected into the control animal. On the
other hand, the cholesterol clearance was signiﬁcantly delayed.
Thus,diabetesresultedintheproductionofanincreasednumberof
lipid- and apo E–deﬁcient chylomicron particles. These alterations
account, in part, for the delay in clearance of these particles.
Keywords Apolipoprotein B48; Apolipoprotein B100; Apolipopro-
tein E; Cholesterol Turnover; Chylomicron Turnover;
Triglyceride Turnover; Type 2 Diabetes
Postprandial lipoprotein metabolism is considerably altered
in diabetes [1, 2], a condition that is associated with an up to
4-fold increase in atherosclerosis. Postprandial hyperglycemia
has been conﬁrmed as a risk factor for mortality [3] and new
treatments with both quick-acting synthetic insulin and short-
acting oral hypoglycemic agents, which signiﬁcantly reduce
postprandial hyperglycemia, are promoted as being beneﬁcial
[4]. So far, there has been little interest in the effect of improved
glycemic control on the postprandial dyslipidemia of diabetes.
This may be due to our poor understanding of the metabolism
of postprandial lipoprotein particles. Our previous studies on
postprandial lipoprotein metabolism in diabetes have demon-
strated abnormalities in the intestinally derived apolipoprotein
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(apo) B48–containing particles and also in the hepatically de-
rived apo B100–containing particles [5–7]. In diabetic patients,
wehavedemonstratedanincreaseinthenumberofparticlesand
an increase in both the cholesterol and triglyceride contents of
each particle [8]. Studies in rats, a model that does not develop
atherosclerosis, have been conﬂicting. Levy and coworkers [9]
have shown that the triglyceride from a chylomicron particle
obtained from a diabetic rat, when injected into a nondiabetic
rat, is cleared more slowly. On the other hand, Feingold and
colleagues [10] showed that a [14C]cholesterol-labeled diabetic
chylomicron,wheninjectedintoanondiabeticrat,wasclearedat
the same rate as a nondiabetic chylomicron. Apo E, synthesised
both by the liver and peripheral tissues including the intestine,
plays an important role in mediating the hepatic recognition
and uptake of the chylomicron. It serves as a ligand for the
low-density lipoprotein (LDL) B/E receptor, the LDL receptor–
related protein (LRP), the lypolysis-stimulated receptor (LSR),
and for cell surface heparin sulphate proteoglycans [11–13].
A reduction in apo E mRNA expression was demonstrated in
cholesterol-feddiabeticrabbits[14],suggestingthatinsulindeﬁ-
ciencydownregulatesapoEmRNAexpression.Overexpression
ofapolipoproteinEintransgenicmicehasbeenshowntoprevent
the development of diabetic hyperlipidemia [15]. Cannulation
of the lymphatic duct allows examination of lipoprotein parti-
cles prior to “ﬁrst pass” alteration, which may be particularly
important in the understanding of the chylomicron, because it is
sorapidlyclearedbytheliver.Thepresentstudywasundertaken
to examine the impact of diabetes on metabolism of the intesti-
nally derived chylomicron particle. We used the cholesterol-fed
alloxan diabetic and nondiabetic rabbit as an animal model of
diabetes and atherosclerosis [16].
MATERIALS AND METHODS
Animals
MaleNewZealandwhiterabbits(Harlan,UK)(nD30)were
housed individually in a reverse light cycle (1 AM to 1 PM light,
1 PM to 1 AM dark). Rabbits were acclimatized for 1 week, with
free access to standard chow and water, and were then changed
to a 0.5% cholesterol diet (Special Diets Service, UK) ad libu-
tim for 6 weeks. Atherosclerosis is easily induced by feeding
rabbits cholesterol [16]. We used an atherosclerotic model be-
cause we were particularly concerned about why diabetes ac-
celerates atherosclerosis. Animals were housed under license
from the Department of Health and experiments were carried
out according to Irish law as administered by the Department of
Health.
At the beginning of the 5th week, diabetes was induced by
intravenous infusion of a 10% (w/v) solution of alloxan mono-
hydrate (150 mg/kg) in physiological saline through a catheter
inserted via a marginal ear vein. To counteract hypoglycemia,
causedbyinsulinreleasefromnecroticbetacellsinthepancreas,
the rabbits were provided with a 20% (w/v) solution of glucose
for the ﬁrst 24 hours. Blood glucose was determined through-
out this period and when animals became hypoglycemic, a 50%
(w/v) glucose solution was given intragastrically. Diabetes was
conﬁrmed 48 hours later with blood glucose >22 mmol/L, as
determined by glucotrend (Boehringer Mannheim, Mannheim,
Germany)strip.Urineketonesweremonitoredwithketostixand
rabbits were not ketotic. Blood glucose and food intake of each
rabbit was monitored daily. Diabetic rabbits (n D 15) were kept
in moderate control by daily subcutaneous injection of insulin
(Ultratard, Novo Nordisk). Animals were diabetic for at least
8 days prior to experiment.
Radiolabeling of Chylomicrons and Lymph
Duct Cannulation
Diabetic (n D 5) and control (n D 5) rabbits were given, by
gavage,20mlofanemulsioncontainingsunﬂoweroil(75%v/v),
H2O (25% v/v), phosphotidylcholine (5% w/v), and 100 ¹Ci
[3H]cholesterol and 50 ¹Ci [14C]linoleic acid. Rabbits were
returned to their cages with access to water. Five hours after
gavage, rabbits were anesthetized by intramuscular injection of
Hypnorm(0.3ml/kg),followedbyintravenousinjectionofHyp-
novel (2 mg/kg). Rabbits were intubated and attached to a Pen-
lon Nufﬁeld anesthesia machine and administered oxygen and
ethrane. A laparotomy was performed and the left kidney tied
off and removed. The mesenteric lymph duct, which lies ven-
trally above the abdominal aorta, was tied off and cannulated by
inserting a 2-mm portex tube. Tubing was exteriorized through
a stab wound in the left side and positioned such that regular
lymph ﬂow occurred. Rabbits were given 50-ml/h warm saline
intravenously. Lymph was collected for 4 hours into tubes con-
taining EDTA (1 mg/ml) and antiproteases were added to pre-
vent oxidation and degradation of the lipoproteins. At the end
of the experiment, blood was taken for determination of plasma
lipoproteinsandapoproteins.Rabbitsweresacriﬁcedbyanover-
dose of euthane.
Preparation of Lymph and Plasma Chylomicrons
Lymph and plasma were overlaid with a 1.006-g/mL density
solution and centrifuged at 20,000 rpm at 10±C for 30 minutes
in a Beckman L7-55 ultracentrifuge using a ﬁxed angle rotor.
Chylomicrons were carefully removed from the top of the
tube with a stretched pasteur pipette. Lymph chylomicrons
(20 ¹l) were added to 4 ml of scintillation ﬂuid and counted
in a 1214 Rack Beta scintillation counter. Lymph and plasma
chylomicrons were kept at 4±C and used for the turnover studies
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Chylomicron Clearance
The clearance study was designed so that lymph chylomi-
crons from control rabbits were injected into paired control
(n D 5) and diabetic (n D 5) rabbits and chylomicrons from
diabetic rabbits were injected into paired control (n D 5) and di-
abeticrabbits(nD5).Radiolabeledlymphchylomicrons(50mg
chylomicrontriglyceride,speciﬁcactivity10,000cpm/mglipid,
approximately) were injected into a marginal ear vein of a con-
scious recipient rabbit. Blood was sampled from the opposite
ear artery before and after injection, at regular intervals for up
to 40 minutes. Blood was centrifuged at 2000 rpm for 10 min-
utes at 4±C to obtain plasma. Radioactivity in 250-¹l samples
of plasma was determined by liquid scintillation counting us-
ing a dual-label mode. In order to calculate the percentage of
radioactivity in plasma after injection, total rabbit plasma vol-
ume was assumed to be 3.4% of rabbit body weight. Area under
the curve from 0 to 15 minutes (area from 0 to 100 deﬁned by
the curve during the 15-minute period) for [3H]cholesterol and
[14C]linoleic acid clearance was calculated.
Lymph and Plasma Lipids
Plasma,lymph,andlipoproteincholesterolweremeasuredby
enzymatic colorimetric methods, using commercially available
kits (Boehringer Mannheim). Plasma, lymph, and lipoprotein
triglycerides and phospholipids were measured with kits from
BioMerieux (Charbonnieres les Bains, France). Plasma high-
density liproprotein (HDL) was measured by using a HDL-C
reagent (Boehringer Mannheim). Protein was estimated by a
modiﬁcation of the Lowry method [17].
Quantiﬁcation of apo B48, apo B100, and apo E
Rabbit lymph and plasma chylomicron apo B48, apo B100,
and apo E were measured using a modiﬁcation of the method
described previously for human plasma apo B48 and apo B100
[8, 18]. Samples were partially delipidated by mixing with di-
ethylether(1:6v/v),centrifugingat14,000rpmfor15minutesat
room temperature, and removing the organic phase. The protein
wasdrieddownandredissolvedin25¹ldenaturingbuffer(2.0%
[v/v] ¯-mercaptoethanol, 4.0% sodium dodecyl sulfate [SDS],
0.01% v/v bromophenol blue, 0.1 mol/l Tris-HCl, pH 6.8, 20%
[v/v] glycerol), heated for 4 minutes at 96±C, and loaded on a
4% to 15% polyacrylamide gel (BioRad, Herculas, CA, USA).
Electrophoresis was for 1 hour at 60 mA constant current in
0.019 mol/l Tris, 0.192 mol/l glycine. Gels were stained for
1 hour with Coomassie Brilliant Blue (0.1% in methanol:acetic
acid:water4:1:5)anddestainedwithseveralchangesofthesame
solvent (Figure 1). Because the chromogenicity of apo B48 has
been shown to be similar to that of apo B100, and the chro-
mogenicity of apo E has been reported to be twice that of apo
FIGURE 1
Typical SDS-PAGE gel of rabbit lymph chylomicron showing
apo B48 and apo B100 separation. Lanes 1 to 3: apo B100
standards; lanes 4 to 7: lymph chylomicrons from 4 different
rabbits showing apo B48 and apo B100 bands.
B100 [19], a protein standard was prepared from LDL (den-
sity 1.025 to 1.063 g/ml) of a single individual, was stored at
¡20±C, and used throughout the study for quantiﬁcation of apo
B48, apo B100, and apo E. Staining was linear within the range
0.1 to 2 ¹g of protein. Apo B100 protein standards (0.2, 0.6,
1.2, and 2 ¹g) were applied to all gels. The bands were quan-
tiﬁed by densitometry using Vilber Lourmat equipment (Vilber
Lourmat Biotechnology, Marne de Vallee, France). Video im-
ages of the gels were generated and imported into Bio1D v6.32
software for analysis (Figure 1). Density values were assigned
to the apo B100 bands of the human LDL and a standard curve
constructed. The values were recalculated by linear regression
and curves with a correlation coefﬁcient >.95 were accepted.
The concentrations of apo B48, apo B100, and apo E were then
determined from this standard. The intra- and interassay varia-
tions (n D 6) for apo B48 were 3.4% and 6.1%, for apo B100
were 5.9% and 8.3%, and for apo E were 1.8% and 3.6%.
Statistical Analysis
Statistical analysis was performed using the Student t test
(paired and unpaired). Area under the curve (AUC) measure-
ments were obtained and correlation coefﬁcients were deter-
mined by linear-regression analysis using Graphpad Prism 2 for
Macintosh (Graphpad Software, San Deigo, CA USA). Inter-
and intraassay variation were expressed as standard deviation/
mean £100. Results were expressed as mean§standard devia-
tion.APvalueof<0.05wasregardedasstatisticallysigniﬁcant.
RESULTS
AnimalcharacteristicsareshowninTable1.Thediabeticrab-
bits were slightly but not signiﬁcantly lighter on the day of the
experiment. There was no signiﬁcant difference in the degree of
diabetes between the diabetic donor and recipient rabbits on the
day of the experiment and no difference in average daily insulin
requirements. Examination of the plasma lipids revealed the ex-
pected increase in plasma triglyceride and decrease in plasma
HDL in the diabetic rabbits. Total cholesterol was higher in the174 C. PHILLIPS ET AL.
TABLE 1
Characteristics and plasma lipids in diabetic and control rabbit after 6 weeks of a high-cholesterol diet
and 1 week of alloxan-induced diabetes
Diabetic donor Control donor Diabetic recipient Control recipient
n D 5n D 5n D 10 n D 10
Body weight (kg) 2.7§0.3 3.0§0.3 3.0§0.4 3.2§0.4
Blood sugar (mmol/L) 19.7§2.3a 5.9§0.2 17.2§3.2a 5.9§0.3
Insulin (U/day) 4.9§4.2 — 4.3§4.3 —
Food intake (g/day) 139§39 130§26 140§27 130§31
Triglyceride (mmol/L) 10.8§13.9a 0.8§0.5 11.6§11b 1.7§2.4
HDL cholesterol (mmol/L) 0.3§0.2a 0.8§0.3 0.5§0.4b 0.9§0.3
Cholesterol (mmol/L) 36.9§27.5 25.7§10.5 52.6§21.9b 33.3§19.4
Free cholesterol (mmol/L) 13.5§9.0 7.1§3.1 28.7§18.1a 12.4§11.4
Esteriﬁed cholesterol (mmol/L) 23.5§18.7 18.6§7.7 23.9§14.5 20.2§15.2
Note. Data are mean§SD.
aP<0.01; bP<0.05 different from control rabbits.
diabetic recipient animals and was due to an increase in free
cholesterol. Plasma chylomicron apo B48 and apo B100 were
signiﬁcantly higher in the diabetic donor animals compared to
control donors (5.2§2.9 and 12.5§4.6 versus 1.4§1.3 and
4.3§4.0 ¹g/ml plasma, P < 0.05) (Table 2). Plasma chylomi-
cron apo E from diabetic donor rabbits was signiﬁcantly lower
than control animals (0.6§0.2 versus 1.3§0.5 mg/mg apo B,
P < 0.02). There was a nonsigniﬁcant increase in cholesterol
triglyceride and phospholipid in diabetic rabbits.
The mean volume of lymph collected in 4 hours was similar
for diabetic and control animals (5.5§3.5 versus 5.2§3.0 ml,
respectively). The constituents of the lymph chylomicrons
(Table 3)usedforclearancestudies,asmg/h,revealedanalmost
5-fold increase in apo B48 (P<0.01) and a more than 3-fold
increase in apo B100 (P<0.05) in the diabetic animals. Look-
ing at the lymph chylomicron composition as mg/mg apo B
(Table3),therewaslesscholesterolandlesstriglyceridepermil-
ligramapoBinthediabeticlymphchylomicron,althoughinthis
small number, the differences were not signiﬁcant. There was a
TABLE 2
Composition of plasma chylomicrons isolated by
ultracentrifugation from donor rabbits at sacriﬁce
Diabetic Control
Apo B48 (¹g/ml plasma) 5.2§2.9a 1.4§1.3
Apo B100 (¹g/ml plasma) 12.5§4.6b 4.3§4.0
Apo B48/B100 0.42§0.2 0.32§0.2
Apo E (mg/mg apo B) 0.6§0.2b 1.3§0.5
Cholesterol (mg/mg apo B) 105§95 84§37
Triglyceride (mg/mg apo B) 94§142 37§10
Phospholipid (mg/mg apo B) 86§173 34§18
Note. Data are mean§SD.
aP<0.05; bP<0.02 different from control rabbits.
signiﬁcantly higher apo B48/apo B100 ratio (P<0.05) and sig-
niﬁcantlylessapoE(0.27§0.01versus0.62§0.07mg/mgapo
B P<0.001) in the diabetic lymph chylomicron. Thus, the dia-
betic animals secreted increased numbers of intestinally derived
chylomicrons with less lipid and less apo E per particle com-
pared to control animals.
TABLE 3
Mean composition of injected lymph chylomicrons from donor
rabbits isolated by ultracentrifugation 5 hours after gavage
with [14C]linoleate and [3H]cholesterol
Diabetic Control
(n D 5) (n D 5)
Composition (mg/h)
Cholesterol 5.1§3.3 2.9§1.1
Free cholesterol 2.1§1.4 1.6§0.7
Esteriﬁed cholesterol 3.0§2.5 1.4§0.6
Triglyceride 41.2§13.3 30.9§24.5
Phospholipid 10.7§4.9 5.8§4.2
Apo B48 0.19§0.10a 0.04§0.02
Apo B100 0.22§0.15b 0.07§0.07
Apo E 0.04§0.03 0.03§0.02
Lipid/apo B 324§285c 2281§1686
Composition (mg/mg apo B)
Cholesterol 32§36 38§20
Free cholesterol 8.5§2.4 9.1§4.2
Esteriﬁed cholesterol 23§34 29§19
Triglyceride 235§210 485§244
Phospholipid 74§40 104§70
Apo E 0.27§0.01d 0.62§0.07
Apo B48/B100 0.97§0.19b 0.62§0.07
Note. Data are mean§SD.
aP < 0.01; bP < 0.05; cP < 0.02; dP < 0.001; different from control
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TABLE 4
Percentage of [3H]cholesterol and [14C]linoleate acid cleared
from the circulation 5 minutes after injection of donor
chylomicrons into recipient animals
[3H]cholesterol [14C]linoleate
(%) (%)
Control-control 84§88 8 § 9
Control-diabetic 63§6a 75§10c
Diabetic-control 67§9b 75§8c
Diabetic-diabetic 61§8a 65§10a
Note. Data are mean§SD.
aP < 0.0005; bP < 0.005; cP < 0.01 versus control chylomicron
into control recipient.
Chylomicron cholesterol clearance and triglyceride clear-
ance during the ﬁrst 15 minutes after injection is shown in
Figure1.Fiveminutesafterinjection,84%§8%ofchylomicron
cholesterol had been cleared from the plasma of control rabbits
that had been injected with control chylomicrons, compared to
67% § 9% when they received chylomicrons from diabetic an-
imals (P < 0.005) (Table 4). Compared to the control animals
that received control chylomicrons, diabetic animals injected
with control chylomicrons had cleared 63%§6% after 5 min-
utes (P < 0.0005) and 61%§8% when they received diabetic
chylomicrons (P < 0.005). Looking at the disappearance of the
FIGURE 2
Chylomicrons isolated from lymph of diabetic and control donor rabbits 4 hours following an oral load of [3H]cholesterol and
[14C]linoleic acid was reinjected into 5 diabetic and 5 control recipient rabbits. (a) Clearance of [3H]cholesterol and (b) clearance
of [14C]linoleic acid. Control donor into control recipient (white squares), diabetic donor into control recipient (black squares),
control donor into diabetic recipient (white circles), and diabetic donor into diabetic recipient (black circles). Data are mean§SE.
TABLE 5
Clearance of chylomicron cholesterol and triglyceride
(0- to 15-minute area under the curve)
[3H]cholesterol [14C]triglyceride
Control-control 426§122 347§103
Control-diabetic 564§106a 511§157c
Diabetic-control 589§116b 419§60
Diabetic-diabetic 648§132b 559§137b
Note. Data are mean§SD.
aP < 0.005; bP < 0.02; cP < 0.05 versus control chylomicron into
control recipient.
triglyceride label, control rabbits given control chylomicrons
removed 88%§9% of the triglyceride by 5 minutes after in-
jection, compared to 75% § 10% when diabetic chylomicrons
were given (P < 0.01). Similarly, 75%§10% of triglyceride
was removed from the plasma of diabetic animals when they re-
ceived control chylomicrons (P < 0.01) and 65%§10% when
diabetic chylomicrons were given (P < 0.0005), compared to
control animals injected with control chylomicrons.
Chylomicron cholesterol and triglyceride, expressed as
AUC (Table 5), was calculated from the clearance curves for
[3H]cholesterol and [14C]linoleic acid over the 15-minute pe-
riod (Figure 2). There was a signiﬁcant delay in cholesterol176 C. PHILLIPS ET AL.
clearance when chylomicrons from control animals were in-
jected into the diabetic recipient, compared to the control chy-
lomicronintothecontrolrecipient(P<0.005).Therewasavery
similardelayinAUCforcholesterolclearancewhenthediabetic
chylomicron was injected into the control recipient (P < 0.02)
and when chylomicrons from the diabetic donor were injected
into the diabetic recipient (P < 0.02, different from control to
control). The pattern for triglyceride clearance was somewhat
different.Triglycerideclearancewassigniﬁcantlydelayedwhen
control chylomicrons were injected into the diabetic recipient
(P < 0.05), compared to control recipient. Injecting chylomi-
cronsfromthediabeticdonorintothediabeticrecipientresulted
in a delay of triglyceride clearance slightly greater than that
found when the control particles were injected into the diabetic
recipient (P < 0.02).
We examined whether the lymph chylomicron apo B or
lipid/apo B composition could have inﬂuenced the clearance
of the particle. However, we were unable to ﬁnd any rela-
tionship between these parameters and either cholesterol or
triglycerideclearance.Therewerepositivecorrelationsbetween
AUC for triglyceride removal and AUC for cholesterol clear-
ance (r D .59, P < 0.01) and also AUC for triglyceride re-
moval and blood glucose on day of experiment (r D .57,
P < 0.01).
DISCUSSION
The cholesterol-fed rabbit is a widely used model for ex-
perimental atherosclerosis research [16]. We therefore fed our
animals a 0.5% cholesterol diet, because this diet is known to
produce atherosclerosis in rabbits [20]. Having decided on our
atheroscleroticmodel,wemadesomeoftheanimalsdiabeticus-
ingalloxan;ourhypothesisbeingthatalterationsinchylomicron
composition might be partly responsible for the delay in chy-
lomicron clearance in diabetes. Examination of chylomicrons
isolated from intestinal lymph in the postprandial state ensures
pure intestinally derived particles, uncontaminated by hepati-
cally derived particles. In rabbits, this lymph contains both apo
B48 and apo B100, because the rabbit has less complete editing
of intestinal apo B100 mRNA to apo B48 mRNA than human
[21]. In the present study, lymph chylomicron particles from
diabetic rabbits contained signiﬁcantly more apo B48 and apo
B100 than particles from control animals, and the triglyceride/
apo B48 ratio was signiﬁcantly reduced in the diabetic animals.
Thus, the major effect of diabetes on the chylomicron was the
production of a larger number of smaller lipid-deﬁcient parti-
cles. The ratio of apo B48/apo B100 in plasma was very differ-
ent, demonstrating the considerable amount of large hepatically
derived very-low-density lipoprotein (VLDL) found in the chy-
lomicron fraction of plasma.
Apo E plays an important regulatory role in chylomicron and
VLDL metabolism through its recognition by the LDL receptor,
the LSR, LRP, and glycosaminoglycans [11–13]. A reduction in
apoEontheparticleoralterationintheapoEgenotype(apoE2)
has been shown to reduce clearance of the particle [22, 23]. Our
resultsshowareductioninapoEonbothlymphandplasmachy-
lomicron particles in the diabetic rabbit, demonstrating that the
apoEdeﬁciencyinlymphisnotcorrectedintheplasma.Lenich
and colleagues [14], some years ago, demonstrated that insulin
deﬁciency in the cholesterol-fed rabbit reduced apo E mRNA in
the liver and adrenals. The intestine, however, was not studied.
In the diabetic rat, Levy and coworkers [9] showed that there
was signiﬁcantly less lymph apo E and apo Al secreted per hour
andmoreapoBthanincontrolanimals.Theydidnotreportpar-
ticle clearance. Feingold and colleagues [10], also using the rat,
showed no difference in clearance of the diabetic chylomicron
particle when injected into normal rats, but there was no infor-
mationonapoE.Inhumanstudies,Syvanneandcoworkers[24],
in a preliminary report, demonstrated enrichment of apo E on
postprandial triglyceride-rich lipoproteins in diabetic patients.
The [3H]cholesterol label in the chylomicron particle from con-
trol rabbits in our study, when injected into the diabetic animal,
resulted in a signiﬁcantly increased retention time, demonstrat-
ingadefectinclearanceoftheparticle.Nocorrectionwasmade
for the increased plasma volume in the diabetic animal, but if
we had used a slightly higher value in the hyperglycemic ani-
mals to correct for the higher osmotic pressure of the glucose,
the results would have demonstrated an even further delay in
clearance. It is possible that the delayed clearance of the chy-
lomicronparticlewheninjectedintothediabeticrecipientwasin
part due to their increased pool size of triglyceride-rich lipopro-
teins. However, clearance of the [3H]cholesterol label was also
impaired when the diabetic chylomicron was injected into the
controlanimal,whereasclearanceof[14C]linoleicacidwasnor-
mal. This suggests that, even with normal hydrolysis of triglyc-
eride, structural abnormalities prevented uptake of the diabetic
chylomicron through its many pathways. Because there was no
difference in the chylomicron triglyceride/apo B between the
2 groups, we used a constant amount of chylomicron triglyc-
eride when injecting the chylomicron particle into the recipient
animals. Delayed clearance of cholesterol in the diabetic recip-
ient animals may in part have been due to the increased parti-
cle load endogenously present in the diabetic recipient animal.
Redgrave and colleagues [25] have shown that particle number
plays a more important role than particle size in determining the
rate of chylomicron clearance. Furthermore, insulin has been
shown to upregulate the B/E receptor [26] and thus the diabetic
state of relative hypoinsulinemia may impede clearance of the
chylomicron through downregulation of the receptor. Delayed
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animals strongly suggests a compositional abnormality of the
particle.
In our study, the deﬁciency in apo E, which is the major
ligand for the hepatic receptors, would seem to be the main
reasonforthedefectiveclearanceofdiabeticchylomicronswhen
injected into control animals. The reason why apo E should be
deﬁcient in particles from the diabetic animals may be related
to the effect of insulin as a regulator of apo E [14] or due to an
inability of apo E to bind to the diabetic particle. It has been
suggested that there is excess of apo E in the serum and that
apo E concentrations are usually well above the minimum level
necessary for normal lipoprotein clearance [22]. The fact that
we found apo E deﬁciency in both the lymph chylomicron and
in the serum chylomicron fraction favors a defect in binding of
apo E to the particle as the explanation.
Examination of turnover of the [14C] label, a marker of
triglyceride clearance, demonstrated the expected delay when
the diabetic lymph chylomicron was injected into the diabetic
animal. We presume this was due to a defect in lipoprotein li-
pase, which is thought to be a major reason for the hypertriglyc-
eridemia of diabetes [27]. It would be expected that an excess
of triglyceride-rich lipoproteins in the circulation would delay
clearance of injected triglyceride-rich particles due to competi-
tion for receptors [28] and of course we had a 5-fold increase in
plasma triglyceride in the diabetic recipient animals. We found
a positive correlation between blood sugar on the day of exper-
iment and triglyceride retention time, again suggesting a rela-
tionship with insulin deﬁciency. The control animal was able
to clear triglyceride from the chylomicron particle produced by
thediabeticanimalovera15-minuteperiod,buttheinitialclear-
ance over the ﬁrst few minutes was signiﬁcantly delayed. Levy
and coworkers [9] showed convincingly that there was delayed
clearance of chylomicron triglyceride from diabetic donor rats
when injected into nondiabetic animals in the ﬁrst few minutes
after injection, but they did not study cholesterol clearance. In
our study, it is interesting that by 15 minutes, the initial delay in
triglyceride clearance had been overcome.
This study demonstrates that in the cholesterol-fed rabbit,
diabetes results in an increase in the number of chylomicron
particles, which are apo E depleted. Both diabetic and control
animals had delayed clearance of diabetic chylomicron choles-
terol, suggesting mechanisms to explain the increased atheroge-
nesis in diabetes, because chylomicron remnant particles have
been shown to be particularly atherogenic.
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